← Eichor
Study identifier: NCT06964425 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Raman Spectroscopy in the Diagnosis of Extrahepatic Cholangiocarcinoma - a Pilot Study

Condition: Cholangiocarcinoma, Extrahepatic · Cholangiocarcinoma of the Extrahepatic Bile Duct · Cholangiocarcinoma, Perihilar  ·  Sponsor: University Hospital Olomouc

PhaseNA
Planned participants20
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Diagnosis of extrahepatic cholangiocarcinoma is challenging because the yield of imaging and tissue sampling is limited. Raman spectroscopy is an optical method based on the analysis of scattered monochromatic light. Raman spectroscopy is able to provide a molecular 'fingerprint' of the tissue to determine its type. The aim of this pilot study was to develop a methodology for in vivo Raman spectroscopy in bile ducts to improve the current diagnostic capabilities of extrahepatic cholangiocarcinoma.

This description comes directly from the study's public registry record.

Talk to the study team

Peter Slodička, M.D.  ·  +420776807612  ·  peter.slodicka@fnol.cz

Václav Ranc, Assoc. Prof.  ·  +420732834753  ·  vaclav.ranc@upol.cz

Always discuss trial participation with your own doctor first.

Locations (1)

Peter SlodičkaOlomouc, Olomouc Region, CzechiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06964425